Baker Bros. Advisors 13F: Cuts ROIV Stake by $24M

Baker Bros. Advisors Trims Stake in Roivant Sciences Ltd.

Baker Bros. Advisors trimmed its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) during its reporting period, according to a Form 13F filing with the SEC. The fund cut its position by 687,294 shares, lowering its total stake by 12.4% down to 4,867,723 shares. At the close of the period, the remaining investment carried a reported value of about $169.1 million.

Position Size and Reduction Details

This reduction leaves Baker Bros. Advisors with a smaller footprint in the biotech firm, moving down from a prior count of 5,555,017 shares. Because 13F disclosures look backward at completed quarters, this snapshot reflects holdings as of May 15, 2026, and may not capture the fund's current share count today.

Roivant Sciences Stock Performance

Shares of Roivant Sciences trade on the NasdaqGS under the ticker ROIV. The stock has moved through a 52-week range between $14.50 and $42.50, and changes hands above its 200-day moving average of $29.49. The company carries a market capitalization of $28.16 billion and does not have a meaningful positive P/E ratio due to negative earnings over the period.

Recent Insider Activity

Company insiders have also been active around the stock recently. On June 30, 2026, Qvt Financial LP and Gold Daniel Allen each sold 12,380 shares for $436,766. President and CIO Mayukh Sukhatme exercised options for 500,000 shares and sold those shares on June 25, 2026, for $17.07 million after acquiring them through an option exercise valued at $1.93 million. Similarly, Eric Venker, President and Immunovant CEO, sold 200,000 shares on June 24, 2026, after acquiring them through an option exercise.

Wall Street Analyst Coverage

Wall Street firms have kept active coverage on the healthcare firm. On October 12, 2026, Wolfe Research downgraded the stock to a Peer Perform rating. Earlier, Stifel initiated coverage on September 17, 2026, with a Buy rating and a $51.00 price target. TD Cowen maintained a Buy rating on September 9, 2026, while raising its target to $55.00. Additional updates came from Guggenheim, Jefferies, HC Wainwright & Co., and Citigroup during late summer and early autumn.

Clinical-Stage Pipeline Overview

Roivant Sciences Ltd. operates as a clinical-stage biopharmaceutical enterprise focused on discovering, developing, and marketing medicines and technologies across several therapeutic areas. Its pipeline features candidates targeting autoimmune diseases, pulmonary hypertension, and other immune-mediated conditions through specialized subsidiaries and proprietary delivery platforms.

What to Watch at Roivant Sciences Ltd.

Investors tracking Roivant Sciences can look ahead to the company's next scheduled earnings report on November 9, 2026. Future SEC filings will provide further insight into how institutional managers adjust their weightings in the biotech sector.